Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam

@article{Bareggi1995EffectsOL,
  title={Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam},
  author={Silvio R Bareggi and Rodolfo Pirola and P. Potvin and Ghislain Devis},
  journal={European Journal of Clinical Pharmacology},
  year={1995},
  volume={48},
  pages={265-268}
}
We studied the pharmacokinetics of a single 0.5-mg i.v. dose of chlordesmethyldiazepam in 8 patients with liver disease and in 12 age-matched healthy controls. The kinetics were also studied of a single 1-mg oral dose in the patients with liver disease. After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Plasma levels and urinary excretion of lormetazepam in patients with liver disease and in healthy volunteers

M Hildebrand, A Hellestern, M Humpel, D Hellenbrecht, R Saller
Eur J Drug Metab Pharmacokinet • 1990
View 1 Excerpt

Similar Papers

Loading similar papers…